• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by West Pharmaceutical Services Inc.

    3/21/25 4:07:14 PM ET
    $WST
    Medical/Dental Instruments
    Health Care
    Get the next $WST alert in real time by email
    DEFA14A 1 tmb-20250320xdefa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934 (Amendment No.           )

    ​

    Filed by the Registrant   x

    Filed by a Party other than the Registrant  ¨

    Check the appropriate box:

    ¨

    Preliminary Proxy Statement

    ¨

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ¨

    Definitive Proxy Statement

    x

    Definitive Additional Materials

    ¨

    Soliciting Material under §240.14a-12

      

     

    West Pharmaceutical Services, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    x

    No fee required.

    ¨

    Fee paid previously with preliminary materials.

    ¨

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

    ​


    GRAPHIC

    Your Vote Counts! WEST PHARMACEUTICAL SERVICES, INC. You invested in WEST PHARMACEUTICAL SERVICES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 6, 2025. Vote Virtually at the Meeting* May 6, 2025 9:30 AM EDT Virtually at: www.virtualshareholdermeeting.com/WST2025 *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V62352-P26361 Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 22, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. WEST PHARMACEUTICAL SERVICES, INC. C/O BROADRIDGE CORPORATE ISSUER SOLUTIONS P.O. BOX 1342 BRENTWOOD, NY 11717 2025 Annual Meeting Vote by May 5, 2025 11:59 PM EDT. For shares held in a Plan, vote by May 1, 2025 11:59 PM EDT.

    GRAPHIC

    THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V62353-P26361 1. Election of Directors; Nominees: 1a. Mark A. Buthman For 1b. William F. Feehery For 1c. Robert F. Friel For 1d. Eric M. Green For 1e. Janet B. Haugen For 1f. Thomas W. Hofmann For 1g. Molly E. Joseph For 1h. Deborah L. V. Keller For 1i. Myla P. Lai-Goldman For 1j. Stephen H. Lockhart For 1k. Douglas A. Michels For 1l. Paolo Pucci For 2. Advisory vote to approve named executive officer compensation; For 3. Amend and Restate Our Amended and Restated Articles of Incorporation to Add a Right For Shareholders to call a Special Meeting; For 4. Amend and Restate Our 2016 Omnibus Incentive Compensation Plan; and For 5. Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

    Get the next $WST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WST

    DatePrice TargetRatingAnalyst
    3/18/2025$275.00Outperform
    Evercore ISI
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    1/8/2025$400.00Buy
    Citigroup
    12/13/2024Peer Perform
    Wolfe Research
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    2/7/2024$323.00 → $536.00Hold → Buy
    Jefferies
    6/16/2023$390.00 → $405.00Neutral → Buy
    BofA Securities
    4/11/2023$330.00 → $400.00Equal-Weight → Overweight
    Stephens
    More analyst ratings

    $WST
    Financials

    Live finance-specific insights

    See more
    • West Announces Leadership Changes

      Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process. Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this ye

      4/24/25 6:10:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces First-Quarter 2025 Results, Increases Adjusted-Diluted EPS Guidance and Declares Third-Quarter 2025 Dividend

      - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2025 and declared a third-quarter 2025 dividend. First-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $698.0 million increased 0.4%; organic net sales growth was 2.1%.Reported-diluted EPS of $1.23, compared to $1.55 in the same period last year.Adjusted-diluted EPS of $1.45, compared to $1.56 in the same period last year.The Company is increasing its full yea

      4/24/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West to Host First-Quarter 2025 Conference Call

      EXTON, Pa., April 10, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter financial results before the market opens on Thursday, April 24, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone particip

      4/10/25 6:00:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Purple Biotech Appoints Shai Lankry as Chief Financial Officer

      U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction REHOVOT, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today the appointment of Shai Lankry as its Chief Financial Officer. "We are pleased to welcome Shai on board. His extensive experience in the U.S. and European biotech and pharma marke

      5/12/25 7:30:00 AM ET
      $GMDA
      $LPTX
      $PPBT
      $WST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical/Dental Instruments
    • West to Participate in Upcoming Investor Conferences

      EXTON, Pa., May 7, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the BofA Securities Annual Healthcare Conference on Wednesday, May 14, 2025 at 2:20 PM PT. It will also present at the William Blair 45th Annual Growth Stock Conference on Thursday, June 5, 2025 at 10:40 AM CT. A live audio webcast of these events will be available in the "Investors" section of the Company's website at www.westpharma.com. Replay of the webcasts will be availabl

      5/7/25 4:30:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Announces Leadership Changes

      Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process. Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this ye

      4/24/25 6:10:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Leadership Updates

    Live Leadership Updates

    See more
    • Sotera Health Appoints Karen Flynn to Board of Directors

      CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

      11/13/23 7:00:14 AM ET
      $CTLT
      $QTRX
      $SHC
      $WST
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • West Announces Executive Leadership Appointments

      EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.

      5/12/22 4:30:00 PM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/13/24 5:17:38 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/14/23 12:37:59 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

      SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

      2/10/22 8:47:14 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    SEC Filings

    See more
    • SEC Form SD filed by West Pharmaceutical Services Inc.

      SD - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      5/21/25 4:15:15 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      5/12/25 4:46:53 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharmaceutical Services Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

      5/8/25 4:46:47 PM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on West Pharm with a new price target

      Evercore ISI initiated coverage of West Pharm with a rating of Outperform and set a new price target of $275.00

      3/18/25 7:58:00 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • West Pharm upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded West Pharm from Hold to Buy and set a new price target of $250.00

      2/14/25 7:09:40 AM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Citigroup initiated coverage on West Pharm with a new price target

      Citigroup initiated coverage of West Pharm with a rating of Buy and set a new price target of $400.00

      1/8/25 8:35:06 AM ET
      $WST
      Medical/Dental Instruments
      Health Care

    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Campbell Shane Alden

      3 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/14/25 4:08:34 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by SVP, Proprietary Segment Campbell Shane Alden

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/14/25 4:04:39 PM ET
      $WST
      Medical/Dental Instruments
      Health Care
    • Director Michels Douglas A was granted 1,071 shares, increasing direct ownership by 2% to 45,171 units (SEC Form 4)

      4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

      5/8/25 5:04:01 PM ET
      $WST
      Medical/Dental Instruments
      Health Care